ProfileGDS5678 / 1424414_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 67% 67% 67% 67% 68% 67% 70% 71% 67% 67% 66% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1021467
GSM967853U87-EV human glioblastoma xenograft - Control 24.09167
GSM967854U87-EV human glioblastoma xenograft - Control 34.0948367
GSM967855U87-EV human glioblastoma xenograft - Control 44.0572367
GSM967856U87-EV human glioblastoma xenograft - Control 54.0482667
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1520168
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1020267
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.345370
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.475971
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0747867
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.074767
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0207166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0558967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0814567